| name | KSB-D05-K0019 |
| description | Special Safety Considerations: Immunogenicity monitoring, drug-drug interaction studies, biomarker safety assessment... |
| version | 1.0.0 |
| domain | D05 |
| domain_name | Clinical Trials PV |
| type | Knowledge |
| proficiency_level | L4 |
| bloom_level | evaluate |
| triggers | ["explain special safety considerations","what is special safety considerations","evaluate special safety considerations"] |
| epa_mapping | EPA-02, EPA-04, EPA-08 |
| cpa_mapping | CPA-01, CPA-07 |
| regulatory_refs | EMA-REG-004, ICH-E6 |
KSB-D05-K0019: Special Safety Considerations
Overview
Domain: D05 - Clinical Trials PV
Type: Knowledge
Proficiency Level: L4 (Proficient - Independent practice)
Bloom Level: Evaluate
Description
Immunogenicity monitoring, drug-drug interaction studies, biomarker safety assessment
Context
- Major Section: Clinical Trial Regulatory Framework and Safety Requirements
- Section: Comprehensive Safety Planning Framework
EPA Mapping
- EPA-02:3004-3005
- EPA-04:3009-3010
- EPA-08:3018-3019
CPA Pathway
Regulatory References
Instructions
When this skill is activated, Claude should:
- Demonstrate L4 proficiency in special safety considerations
- Apply evaluate level cognitive skills to evaluate the topic
- Reference relevant regulatory guidance (EMA-REG-004, ICH-E6)
- Connect to related EPAs: EPA-02, EPA-04, EPA-08
Key Competencies
- Immunogenicity monitoring, drug-drug interaction studies, biomarker safety assessment
Assessment Criteria
- Can evaluate core concepts independently
- Demonstrates understanding of regulatory context
- Applies knowledge appropriately to PV scenarios
Related Skills
- Other D05 skills in Comprehensive Safety Planning Framework
- Cross-domain integrations per DAG architecture
Generated from PV KSB Framework v1.0 | 2025-12-31
